date:Dec 10, 2012
t of CHF 0.25 million in cash and provide 1.077 million Evolva shares (0.6% of currently issued capital);
Pay up to CHF 0.8 million in cash and/or shares over the next 12 months; and
Pay a single digit percentage royalty on resveratrol sales until cumulative resveratrol sales by Evolva reach c. CHF 65 million - after which point, no more royalties will be due.
Copenhagen Life Science Advisors assisted in the preparation and execution of the transaction between Fluxome and Evolva.
As a co